Tenax Therapeutics, Inc.
TENX
$5.80
$0.030.52%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 64.55% | 43.30% | 29.48% | -3.22% | 15.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 118.34% | 118.14% | 197.04% | 153.87% | 30.78% |
| Operating Income | -118.34% | -118.14% | -197.04% | -153.87% | -30.78% |
| Income Before Tax | -94.27% | -100.84% | -223.21% | -170.03% | -26.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -94.27% | -100.84% | -223.21% | -170.03% | -26.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -94.27% | -100.84% | -223.21% | -170.03% | -26.57% |
| EBIT | -118.34% | -118.14% | -197.04% | -153.87% | -30.78% |
| EBITDA | -118.62% | -118.15% | -197.13% | -153.89% | -30.65% |
| EPS Basic | 98.35% | 97.17% | 54.37% | 74.25% | 89.16% |
| Normalized Basic EPS | 98.36% | 97.17% | 54.37% | 74.18% | 89.17% |
| EPS Diluted | 98.35% | 97.17% | 54.37% | 74.25% | 89.16% |
| Normalized Diluted EPS | 98.36% | 97.17% | 54.37% | 74.18% | 89.17% |
| Average Basic Shares Outstanding | 11,712.01% | 6,993.90% | 608.21% | 948.24% | 1,067.19% |
| Average Diluted Shares Outstanding | 11,712.01% | 6,993.90% | 608.21% | 948.24% | 1,067.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |